BioDrain Medical to Present at National Investment Banking Association Conference in Boston, August 17-19, 2011 Print E-mail
By Marketwire - Medical and Healthcare   
Wednesday, 17 August 2011 07:00

SOURCE: BioDrain Medical, Inc.

BioDrain Medical to Present at National Investment Banking Association Conference in Boston, August 17-19, 2011

MINNEAPOLIS, MN--(Marketwire - Aug 17, 2011) - BioDrain Medical, Inc. (OTCBB: BIOR) (OTCQB: BIOR), producer of the FDA cleared Streamway® System for automated surgical fluid disposal, today announced that Alan Shuler, the Company's Secretary and Acting Chief Financial Officer, will present details of the Company's growing commercialization at the National Investment Banking Association (NIBA) Conference being held at the Omni Parker House in Boston on August 17-19, 2011.

Mr. Shuler stated, "I am excited to present our latest developments in commercializing BioDrain's unique, patented, FDA approved Streamway System to NIBA's audience of investment banking, corporate finance and investment brokerage firms. We are creating an infrastructure to facilitate and support the rapid sale and placement of the Streamway System in operating rooms across the country. Our newly expanded sales rep force is rapidly increasing our ability to demonstrate the Streamway's continuous, automated and

cost effective process to an expanding number of hospitals and

Error. Page cannot be displayed. Please contact your service provider for more details. (17)

surgical centers. As these medical centers discover the safety, low cost, improved environmental impact and
efficiency of the Streamway System, we anticipate a corresponding conversion of these demonstrations into purchase orders, and we are preparing to meet the demand."

About BioDrain Medical, Inc.
BioDrain Medical, Inc. has a fully automated, patented, FDA cleared, surgical fluid disposal system that virtually eliminates operating room workers' exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment. Today's manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain's Streamway System fully automates the collection, measurement and disposal of surgical fluids resulting in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving the Occupational State and Health Association (OSHA) and other regulatory compliance, and 3) improving the efficiency of the operating room (and thereby making surgeries more profitable).

BioDrain's Streamway System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease infected canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to come. With the installation of BioDrain's Streamway System, the number of canisters can be significantly reduced. BioDrain Medical, Inc. makes the operating room and our environment safer, cleaner, and better. BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country. For additional information, please visit: www.biodrainmedical.com.

Forward-looking Statements:
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See the company's most recent Quarterly Report on Form 10-Q and related 8-K filings.

Read more http://www.marketwire.com/mw/release.do?id=1550614&sourceType=3




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter

BMR:1